{"doi":"10.1210/jc.82.3.876","title":"Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment","abstract":null,"journal":"The Journal of Clinical Endocrinology & Metabolism","year":null,"id":41908,"datarank":4.613694315581332,"base_score":4.442651256490317,"endowment":4.442651256490317,"self_citation_contribution":0.6663976884735476,"citation_network_contribution":3.947296627107785,"self_endowment_contribution":0.6663976884735476,"citer_contribution":3.947296627107785,"corpus_percentile":null,"corpus_rank":null,"citation_count":84,"citer_count":81,"citers_with_citation_signal":64,"citers_with_endowment":64,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":4.442651256490317,"endowment":4.442651256490317,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"18998881","pmcid":null,"openalex_id":"https://openalex.org/W4243640340","authors":[],"funders":[],"total_grants":0,"fwci":2.7454,"citation_percentile":0.90356966,"influential_citations":0,"citation_trend":[{"year":2012,"count":2},{"year":2013,"count":7},{"year":2016,"count":5},{"year":2020,"count":1},{"year":2023,"count":1},{"year":2026,"count":1}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"https://academic.oup.com/jcem/article-pdf/82/3/876/11058967/jcem0876.pdf","host_type":"journal"},{"url":"https://academic.oup.com/jcem/article-pdf/82/3/876/11058967/jcem0876.pdf","host_type":"publisher"},{"url":"http://academic.oup.com/jcem/article-pdf/82/3/876/11058967/jcem0876.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1210/jc.82.3.876","host_type":"journal"}],"fields_of_study":["Pituitary Gland Disorders and Treatments","Neuroblastoma Research and Treatments","Adrenal and Paraganglionic Tumors"],"mesh_terms":[],"keywords":["Cabergoline","Bromocriptine","Prolactinoma","Dopamine agonist","Medicine","Dopamine","Pituitary tumors","Pharmacology","Internal medicine","Endocrinology","Oncology","Prolactin","Dopaminergic"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-13T14:25:00.113110Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}